Skip to main content
SpringerLink
Log in

Intravesical Therapy for Bladder Cancer

  • Chapter
  • First Online:
Urological Oncology

  • 1629 Accesses

Abstract

The majority of patients with urothelial carcinoma (UCa) present with non-muscle invasive (superficial) disease. Whilst some patients may be managed by endoscopic transurethral surgery of the bladder tumour (TURBT) alone, a significant proportion will recur, and some may progress to muscle invasive disease. As a consequence intravesical chemotherapy and immunotherapy are important adjuvant treatments in combination with a thorough and complete TURBT.

The current evidence underpinning the choice of intravesical treatment in various tumour risk groups is reviewed in this chapter, along with the treatment regimes and toxicity associated with the different treatments. Arguments for and against single-instillation chemotherapy are analysed. The relative merits of intravesical chemotherapy and Bacille Calmette-Guerin (BCG) treatment are discussed in terms of prevention of tumour recurrence, prevention of tumour progression, and toxicity. The question of whether maintenance BCG is necessary is also considered.

Finally, the management of patients who have failed primary intravesical treatment is reviewed, and newer treatments that are being developed for this group of patients are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jones HC, Swinney J. The treatment of tumours of the bladder by transurethral resection. Br J Urol. 1962;34:215–20.

    Article  CAS  PubMed  Google Scholar 

  2. Jones H, Swinney J. Thiotepa in the treatment of tumours of the bladder. Lancet. 1961;2(7203):615–8.

    Article  CAS  PubMed  Google Scholar 

  3. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.

    CAS  PubMed  Google Scholar 

  4. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology. 2000;55(2):161–8.

    Article  CAS  PubMed  Google Scholar 

  5. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001;21(1B):765–9.

    CAS  PubMed  Google Scholar 

  6. Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol. 2004;27(5):522.

    Article  PubMed  Google Scholar 

  7. Sylvester RJ, van der Meijden APM, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86–91; discussion 91–2.

    Article  CAS  PubMed  Google Scholar 

  8. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604.

    Article  CAS  PubMed  Google Scholar 

  9. Kuroda M, Niijima T, Kotake T, Akaza H. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer – The 6th Trial of the Japanese Urological Cancer Research Group. A Randomised Trial of Intravesical Epirubicin at Dose 20mg/40ml, 30mg/40ml, 40mg/40ml. Eur Urol. 2004;45(5):600–5.

    Article  CAS  PubMed  Google Scholar 

  10. Oosterlinck W, Kurth KH, Schröder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993;149(4):749–52.

    CAS  PubMed  Google Scholar 

  11. Tolley DA, Parmar MKB, Grigor KM, Lallemand G. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol. 1996;155(4):1233–8.

    Article  CAS  PubMed  Google Scholar 

  12. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–77.

    Article  PubMed  Google Scholar 

  13. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997–1008.

    Article  PubMed  Google Scholar 

  14. Kaasinen E, Rintala E, Hellström P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol. 2002;42(2):167–74.

    Article  PubMed  Google Scholar 

  15. Gudjónsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009;55(4):773–80.

    Article  PubMed  Google Scholar 

  16. Sylvester R, Oosterlinck W. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Has the evidence changed. Eur Urol. 2009;56:43–5.

    Article  PubMed  Google Scholar 

  17. Cai T, Nesi G, Tinacci G, et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol. 2008;180(1):110–5.

    Article  CAS  PubMed  Google Scholar 

  18. Berrum-Svennung I, Granfors T, Jahnson S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol. 2008;179(1):101–6.

    Article  PubMed  Google Scholar 

  19. O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol. 2011;60(4):703–10.

    Article  PubMed  Google Scholar 

  20. Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer. 1999;86(9):1818–26.

    Article  CAS  PubMed  Google Scholar 

  21. Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol. 2000;53(7):676–80.

    Article  CAS  PubMed  Google Scholar 

  22. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996;156(6):1934–40; discussion 1940–1.

    Article  CAS  PubMed  Google Scholar 

  23. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53(4):709–19.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term Intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non–muscle-invasive bladder carcinoma. Eur Urol. 2007;52(4):1123–30.

    Article  CAS  PubMed  Google Scholar 

  25. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485–90.

    Article  CAS  PubMed  Google Scholar 

  26. Nieuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol. 2003;43(6):711–2.

    Article  PubMed  Google Scholar 

  27. Doherty AP, Trendell-Smith N, Stirling R, et al. Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int. 1999;83(4):420–3.

    Article  CAS  PubMed  Google Scholar 

  28. Cliff A, Romaniuk C, Parr N. Perivesical inflammation after early mitomycin C instillation. BJU Int. 2000;85:556–7.

    Article  CAS  PubMed  Google Scholar 

  29. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137(1):155–8.

    CAS  PubMed  Google Scholar 

  30. Ratliff TL, Ritchey JK, Yuan JJ, et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150(3):1018–23.

    CAS  PubMed  Google Scholar 

  31. Matzinger P. An innate sense of danger. Semin Immunol. 1998;10(5):399–415.

    Article  CAS  PubMed  Google Scholar 

  32. Luo Y, Yamada H, Evanoff DP, Chen X. Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol. 2006;146(1):181–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Luo Y, Chen X, Downs TM, et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol. 1999;162(4):2399–405.

    CAS  PubMed  Google Scholar 

  34. Lamm DL, DeHaven JI, Shriver J, Sarosdy MF. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. J Urol. 1991;145(4):738–40.

    CAS  PubMed  Google Scholar 

  35. Lamm DL, Thor DE, Harris SC, et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38–40.

    CAS  PubMed  Google Scholar 

  36. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209–16.

    Article  CAS  PubMed  Google Scholar 

  37. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.

    Article  CAS  PubMed  Google Scholar 

  38. Sylvester R, van der Meijden A. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–70.

    Article  CAS  PubMed  Google Scholar 

  39. Herr HW, Dalbagni G, Donat SM. Bacillus Calmette-Guérin without maintenance therapy for high-risk non–muscle-invasive bladder cancer. Eur Urol. 2011;60(1):32–6.

    Article  PubMed  Google Scholar 

  40. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682–6.

    Article  PubMed  Google Scholar 

  41. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–5.

    Article  PubMed  Google Scholar 

  42. van der Meijden APM, Sylvester RJ, Oosterlinck W, et al. EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44(4):429–34.

    Google Scholar 

  43. Martínez-Piñeiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89(7):671–80.

    Article  PubMed  Google Scholar 

  44. Ojea A, Nogueira JL, Solsona E, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007;52(5):1398–406.

    Article  CAS  PubMed  Google Scholar 

  45. Witjes JA, Caris CT, Mungan NA, et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol. 1998;160(5):1668–71; discussion 1671–2.

    Article  CAS  PubMed  Google Scholar 

  46. Kaasinen E, Wijkström H, Malmstrom P-U, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol. 2003;43(6):637–45.

    Article  CAS  PubMed  Google Scholar 

  47. Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol. 1999;162(2):339–42.

    Article  CAS  PubMed  Google Scholar 

  48. Malmstrom P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–56.

    Article  PubMed  Google Scholar 

  49. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–23.

    Article  PubMed  Google Scholar 

  50. Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol. 2003;26(4):402–7.

    CAS  PubMed  Google Scholar 

  51. Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423–30.

    Article  PubMed  Google Scholar 

  52. Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260–5.

    Article  PubMed  Google Scholar 

  53. Duchek M, Johansson R, Jahnson S, et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol. 2010;57(1):25–31.

    Article  CAS  PubMed  Google Scholar 

  54. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–73.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935–9.

    Article  CAS  PubMed  Google Scholar 

  56. Witjes J, Palou J, Soloway M, Lamm D. Clinical practice recommendations for the prevention and management of intravesical therapy–associated adverse events. Eur Urol Suppl. 2008;7(10):667–74.

    Article  CAS  Google Scholar 

  57. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169(5):1706–8.

    Article  CAS  PubMed  Google Scholar 

  58. Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol. 2000;164(3 Pt 1):685–9.

    Article  CAS  PubMed  Google Scholar 

  59. Gallagher BL, Joudi FN, Maymí JL, O’Donnell MA. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology. 2008;71(2):297–301.

    Article  PubMed  Google Scholar 

  60. Joudi FN, Smith BJ, O’Donnell MA, National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24(4):344–8.

    Article  CAS  PubMed  Google Scholar 

  61. Olsson CA, Chute R, Rao CN. Immunologic reduction of bladder cancer recurrence rate. J Urol. 1974;111(2):173–6.

    CAS  PubMed  Google Scholar 

  62. Lamm DL, DeHaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol. 2000;37 Suppl 3:41–4.

    Article  CAS  PubMed  Google Scholar 

  63. Kowalski M, Entwistle J, Cizeau J, et al. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients. Drug Des Devel Ther. 2010;4:313–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Malmström PU, Wijkström H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161(4):1124–7.

    Article  PubMed  Google Scholar 

  65. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729–34.

    Article  CAS  PubMed  Google Scholar 

  66. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology. 2005;66(4):726–31.

    Article  PubMed  Google Scholar 

  67. Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116(8):1893–900.

    Article  PubMed  Google Scholar 

  68. Porena M, Del Zingaro M, Lazzeri M, et al. Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int. 2010;84(1):23–7.

    Article  CAS  PubMed  Google Scholar 

  69. Bohle A, Leyh H, Frei C, et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 2009;56(3):495–503.

    Article  PubMed  Google Scholar 

  70. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010;75:134–7.

    Article  PubMed  Google Scholar 

  71. Lammers RJM, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81–93.

    Article  PubMed  Google Scholar 

  72. Shen Z, Shen T, Wientjes MG, et al. Intravesical treatments of bladder cancer: review. Pharm Res. 2008;25(7):1500–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  73. Witjes AJ, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27(3):319–24.

    Article  Google Scholar 

  74. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol. 2009;182(4):1313–7.

    Article  CAS  PubMed  Google Scholar 

  75. Di Stasi S, Giannantoni A, Stephen R. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777–82.

    Article  PubMed  Google Scholar 

  76. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12(9):871–9.

    Article  PubMed  Google Scholar 

  77. Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology. 2003;61(2):338–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospitals Leicester, Leicester, UK

    Benjamin L. Jackson MB, ChB (Hons), FRCS (Urol), T. R. Leyshon Griffiths BSc, MD, FRCS (Urol) & J. Kilian Mellon MD, FRCS (Urol)

Authors
  1. Benjamin L. Jackson MB, ChB (Hons), FRCS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. R. Leyshon Griffiths BSc, MD, FRCS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Kilian Mellon MD, FRCS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Kilian Mellon MD, FRCS (Urol) .

Editor information

Editors and Affiliations

  1. Department of Urology, Homerton University Hospital & Formerly St. Bartholomew's Hospital, London, United Kingdom

    Vinod H. Nargund

  2. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA

    Derek Raghavan

  3. Radiation Oncology, Cedars Sinai Cancer Center, Los Angeles, California, USA

    Howard M. Sandler

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Jackson, B.L., Griffiths, T.R.L., Mellon, J.K. (2015). Intravesical Therapy for Bladder Cancer. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_32

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-482-1_32

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-481-4

  • Online ISBN: 978-0-85729-482-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation